94212-06-3

Basic information

• Product Name: Phenol, 4-(1-phenyl-1H-benzimidazol-2-yl)-
• CAS NO: 94212-06-3
• Molecular Formula: C19H14N2O
• Molecular Weight: 286.333
• Mol File: 94212-06-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Phenol, 4-(1-phenyl-1H-benzimidazol-2-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-(1-phenyl-1H-benzimidazol-2-yl)-(94212-06-3)
• EPA Substance Registry System: Phenol, 4-(1-phenyl-1H-benzimidazol-2-yl)-(94212-06-3)

Safety Data

• Hazardous Substances Data: 94212-06-3(Hazardous Substances Data)

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 100-07-2 4-methoxy-benzoyl chloride 
• 2620-84-0 2-(4-methoxyphenyl)-1-phenyl-1H-benzo[d]imidazole 

Downstream Products

• 175713-97-0 1-phenyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-benzo[d]imidazole 
• 175713-98-1 1-phenyl-2-[4-[3-(piperidin-1-yl)propoxy]phenyl]-benzimidazole 

Relevant articles and documents

Dendritic iridium complex electroluminescent material capable of solution processing and synthetic method thereof

The invention discloses a dendritic iridium complex electroluminescent material capable of solution processing and a synthetic method thereof. The molecular structure consists of two parts, one part is an iridium complex with room temperature phosphorescence property as a luminescent core, the other part is a racial with high triplet state energy level as a peripheral branch radial, and the two parts are connected through a non-conjugated radical. The molecule is of the structure as shown in the specification, wherein C1 to C3 are ionic dendritic iridium complexes, and C4 to C6 are neutral dendritic iridium complexes of similar structure. R1 and R2 are high triplet state energy level radicals with non-conjugated radical ends. The problems of synthesis, purification, device preparation technology and cost, existing in wet process preparation devices, of iridium complex materials can be solved.

Methods of treating or preventing interstitial cystitis

PCT No. PCT/US97/03895 Sec. 371 Date Aug. 25, 1998 Sec. 102(e) Date Aug. 25, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/33873 PCT Pub. Date Sep. 18, 1997This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.

METHODS FOR TREATING A PHYSIOLOGICAL DISORDER ASSOCIATED WITH BETA-AMYLOID PEPTIDE

This invention provides substituted benzimidazoles which are useful in treating or preventing conditions associated with beta-amyloid peptide. Some such conditions associated with beta-amyloid peptide include Alzheimer's Disease, Down's Symdrome and amyloidosis of the Dutch type